GlassScriptPhysician profile
Emily Aranyos
NPI 1215484829
$841.54
in general payments reported to CMS, 2019-2025
20 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.67 · 2022: $16.02 · 2023: $195 · 2024: $276 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $150.26 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $75.36 | 2023-2025 | Wegovy |
| Amgen INC. | $68.51 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $65.49 | 2024-2025 | Rexulti |
| Biogen, INC. | $54.69 | 2024 | Spinraza |
| Glaxosmithkline, LLC. | $52.38 | 2024-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $47.40 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $41.57 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $35.21 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $33.72 | 2023 | |
| Ucb, INC. | $32.26 | 2024 | Nayzilam |
| Merck Sharp & Dohme LLC | $31.16 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $23.81 | 2025 | Keveyis |
| Janssen Pharmaceuticals, INC | $23.54 | 2023 | Xarelto |
| Shield Therapeutics INC | $21.02 | 2023 | Accrufer |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.62 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.55 | 2024 | Eliquis |
| Seqirus USA INC | $16.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.98 | 2024 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $13.99 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Aranyos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.